DelveInsight’s, “Polycythemia Vera Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Polycythemia Vera pipeline landscape. It covers the Polycythemia Vera pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Polycythemia Vera therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Polycythemia Vera Pipeline @ https://www.delveinsight.com/sample-request/polycythemia-vera-pipeline-insight

Key Takeaways from the Polycythemia Vera Pipeline Report

• On June 05, 2026- Ono Pharmaceutical Co., Ltd. initiated a phase 3 study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy. The study will be conducted in three sequential parts (Part 1a blinded treatment, Part 1b open-label treatment, & Part 2 long-term extension). Participants may receive treatment for up to 156 weeks.
• On June 04, 2026- Novartis Pharmaceuticals conducted a trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.
• On June 01, 2026- Ionis Pharmaceuticals Inc. highlighted a Phase 2a study of sapablursen in up to 40 participants with PD-PV. The study consists of 4 periods: 1) Screening Period: up to 7 weeks; 2) Treatment Period: 37 weeks 3) Treatment Extension Period: 36 weeks; 4) Post-treatment Period: 13 weeks.
• DelveInsight’s Polycythemia Vera Pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Polycythemia Vera treatment.
• The leading Polycythemia Vera Companies such as Merck Sharp & Dohme LLC, Chengdu Zenitar Biomedical Technology Co., Ltd., Prelude Therapeutics, Italfarmaco, Mabwell (Shanghai) Bioscience Co., Ltd., Silence Therapeutics plc, Incyte Corporation, Hangzhou GluBio Pharmaceutical Co., Ltd., Ajax Therapeutics, Inc., Syntara and others.
• Promising Polycythemia Vera Pipeline Therapies such as Rusfertide, Givinostat, Hydroxyurea, Bomedemstat, PTG-300, SLN124, Ruxolitinib, P1101 (Ropeginterferon alfa-2b-njft), AOP2014 and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Polycythemia Vera Treatment Drugs

Polycythemia Vera Overview

Polycythemia vera (PV) is a myeloproliferative neoplastic disorder involving uncontrolled red blood cell production resulting in elevated red blood cell (RBC) mass. There is often a concurrent stimulation of myeloid and megakaryocytic lineages, leading to increased white blood cell and platelet production. The current understanding of pathophysiology involves increased sensitivity to growth factors due to an abnormal hematopoietic cell clone. Signs and symptoms, including headache, dizziness, claudication, thrombosis, are a consequence of increased blood viscosity.

Polycythemia Vera Emerging Drugs

• Bomedemstat: Merck Sharp & Dohme LLC

Bomedemstat (MK-3543) is an investigational small molecule, irreversible LSD1 inhibitor being developed by Merck. LSD1 regulates the proliferation of hematopoietic stem cells, playing an essential role in cell differentiation and maturation. Bomedemstat is being evaluated in a wide range of MPNs, including ET, MF and PV. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Polycythemia Vera.

• Flonoltinib: Chengdu Zenitar Biomedical Technology Co., Ltd

Flonoltinib, an orally bioavailable dual inhibitor of both Janus-associated kinase 2 (JAK2) and of FMS-like tyrosine kinase 3 with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon oral administration, flonoltinib targets, binds to and inhibits the activity of both JAK2 and FLT3. This prevents the activation of the JAK/signal transducer and activator of transcription (STAT) signaling pathway and the activation of STAT3 and STAT5 as well as FLT3-mediated signaling. This may lead to an induction of apoptosis and a decrease in proliferation of tumor cells in which JAK2 and FLT3 are overexpressed. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Polycythemia Vera.

• PRT12396: Prelude Therapeutics

PRT12396 is an oral, highly selective, allosteric inhibitor of the mutant JAK2V617F protein, specifically targeting the JH2 (pseudokinase) domain. Developed by Prelude Therapeutics for the treatment of myeloproliferative neoplasms (MPNs), this agent is designed to selectively inhibit cells carrying the mutation while sparing wild-type JAK2, which is expected to improve tolerability and reduce mutant allele burden. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Polycythemia Vera.

The Polycythemia Vera Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Polycythemia Vera with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Polycythemia Vera Treatment.
• Polycythemia Vera Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Polycythemia Vera Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Polycythemia Vera market

Explore groundbreaking therapies and clinical trials in the Polycythemia Vera Pipeline @ New Polycythemia Vera Drugs

Polycythemia Vera Companies

Merck Sharp & Dohme LLC, Chengdu Zenitar Biomedical Technology Co., Ltd., Prelude Therapeutics, Italfarmaco, Mabwell (Shanghai) Bioscience Co., Ltd., Silence Therapeutics plc, Incyte Corporation, Hangzhou GluBio Pharmaceutical Co., Ltd., Ajax Therapeutics, Inc., Syntara and others.

Polycythemia Vera Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Polycythemia Vera Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Polycythemia Vera Market Drivers and Barriers

Scope of the Polycythemia Vera Pipeline Report

Coverage- Global

Polycythemia Vera Companies- Merck Sharp & Dohme LLC, Chengdu Zenitar Biomedical Technology Co., Ltd., Prelude Therapeutics, Italfarmaco, Mabwell (Shanghai) Bioscience Co., Ltd., Silence Therapeutics plc, Incyte Corporation, Hangzhou GluBio Pharmaceutical Co., Ltd., Ajax Therapeutics, Inc., Syntara and others.

Polycythemia Vera Pipeline Therapies- Rusfertide, Givinostat, Hydroxyurea, Bomedemstat, PTG-300, SLN124, Ruxolitinib, P1101 (Ropeginterferon alfa-2b-njft), AOP2014 and others.

Polycythemia Vera Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

Polycythemia Vera Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth pipeline report today! @ Polycythemia Vera Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Polycythemia Vera: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Polycythemia Vera– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Bomedemstat: Merck Sharp & Dohme LLC
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Flonoltinib: Chengdu Zenitar Biomedical Technology Co., Ltd
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. PRT12396: Prelude Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Polycythemia Vera Key Companies
21. Polycythemia Vera Key Products
22. Polycythemia Vera- Unmet Needs
23. Polycythemia Vera- Market Drivers and Barriers
24. Polycythemia Vera- Future Perspectives and Conclusion
25. Polycythemia Vera Analyst Views
26. Polycythemia Vera Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/polycythemia-vera-pipeline-insight